$23.84
+1.71%Oct 2, 2026, 12:00 UTC
Surrozen announced that the FDA clearance milestone triggers the second closing of its March 2025 private placement, expected to provide approximately $95.1 million in gross proceeds.
Source:Oct 2, 2026, 12:00 UTC
The FDA cleared Surrozen's Investigational New Drug application for SZN-8141 for the treatment of diabetic macular edema, allowing the company to advance the program into clinical development.
Source:Sep 8, 2026, 12:30 UTC
Surrozen submitted an Investigational New Drug application to the U.S. Food and Drug Administration for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody, for the treatment of diabetic macular edema.